Sivelestat sodium hydrate is a selective inhibitor of
neutrophil elastase, which is effective in
acute lung injury associated with
systemic inflammatory response syndrome. However, the effectiveness of
sivelestat in
sepsis has not been fully examined. In the present study, the effect of
sivelestat on
severe sepsis in a rat cecal
ligation and
puncture (CLP) model was investigated. Adult male Sprague-Dawley rats underwent CLP and were randomly divided into two groups:
sivelestat-treated group and saline-treated controls. The serum concentrations of several inflammatory mediators were measured.
Hematoxylin-
eosin staining, and immunohistochemical staining for high-mobility group box chromosomal
protein 1 (
HMGB1),
IL-8, and CD68 were performed on the lungs to assess pathological changes found 12 h after the CLP procedure. Treatment with
sivelestat significantly improved the survival rate of the post-CLP septic animals (P = 0.030).
Sivelestat also induced a significant reduction in serum IL-1beta (P = 0.038) and
IL-10 (P = 0.008) levels in these CLP rats. Serum
HMGB1 levels had no significant difference between the
sivelestat-treated and the control group. The lungs from
sivelestat-treated rats exhibited less severe pathological changes and decreased the numbers of
HMGB1,
IL-8, and CD68-positive cells (P < 0.001).
Sivelestat significantly improved survival rate of rats with clinically relevant
sepsis, possibly by attenuating
sepsis-induced systemic inflammatory response and
lung injury. This may explain the implicated health benefits of
sivelestat in reducing morbidity and mortality from
sepsis.